Skip to main content

Table 1 Changes in clinical measures of disease activity over 12 weeks on anti-TNF treatment in 25 patients with rheumatoid arthritis

From: Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis

Parameter Baseline Week 1 Week 4 Week 12
  Mean ± SD Mean ± SD P value Mean ± SD P value Mean ± SD P value
DAS28-ESR 5.72 ± 0.84 4.47 ± 1.14 **** 4.26 ± 1.13 **** 2.87 ± 1.11 ****
DAS28-CRP 5.28 ± 0.98 3.98 ± 1.09 **** 3.85 ± 1.13 **** 2.36 ± 1.04 ****
SJC28 7.68 ± 5.36 4.42 ± 3.89 ** 4.54 ± 4.28 ** 3.00 ± 3.83 ***
TJC28 14.88 ± 8.51 8.95 ± 6.66 *** 8.76 ± 6.69 ** 4.68 ± 4.93 ***
CRP 15.74 ± 18.26 5.29 ± 6.39 *** 10.75 ± 24.15 *** 8.73 ± 16.48 ***
ESR 27.21 ± 22.67 20.50 ± 19.36 ** 19.96 ± 14.88 ** 20.45 ± 16.73 ns
  1. Data are presented as mean ± SD. DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SJC28 swollen joint count out of 28 joints, TJC28 tender joint count out of 28 joints
  2. Each time point on treatment was compared to baseline using Wilcoxon matched pairs test; **P < 0.001, ***P < 0.0005, ****P < 0.0001